156 related articles for article (PubMed ID: 38324313)
21. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
22. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.
Chiu PK; Leow JJ; Chiang CH; Mok A; Zhang K; Hsieh PF; Zhu Y; Lam W; Tsang WC; Fan YH; Lin TP; Chan TY; Leung CH; Teoh JY; Chu PS; Zhu G; Ye DW; Wu HC; Tan TW; Tsu JH; Ng CF; Chiong E; Huang CY
J Urol; 2023 Jul; 210(1):88-98. PubMed ID: 37036248
[TBL] [Abstract][Full Text] [Related]
23. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).
Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38402105
[TBL] [Abstract][Full Text] [Related]
24. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI.
Nordström T; Jäderling F; Carlsson S; Aly M; Grönberg H; Eklund M
BMJ Open; 2019 Jun; 9(6):e027816. PubMed ID: 31201191
[TBL] [Abstract][Full Text] [Related]
25. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
Kim M; Ryu H; Lee HJ; Hwang SI; Choe G; Hong SK
World J Urol; 2021 May; 39(5):1463-1471. PubMed ID: 32696126
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7.
Scott E; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Urol Oncol; 2017 Mar; 35(3):120. PubMed ID: 28215847
[TBL] [Abstract][Full Text] [Related]
27. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
29. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
[TBL] [Abstract][Full Text] [Related]
30. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
[TBL] [Abstract][Full Text] [Related]
31. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.
Hansen NL; Barrett T; Kesch C; Pepdjonovic L; Bonekamp D; O'Sullivan R; Distler F; Warren A; Samel C; Hadaschik B; Grummet J; Kastner C
BJU Int; 2018 Jul; 122(1):40-49. PubMed ID: 29024425
[TBL] [Abstract][Full Text] [Related]
32. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
[TBL] [Abstract][Full Text] [Related]
33. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
34. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
Hugosson J; Månsson M; Wallström J; Axcrona U; Carlsson SV; Egevad L; Geterud K; Khatami A; Kohestani K; Pihl CG; Socratous A; Stranne J; Godtman RA; Hellström M;
N Engl J Med; 2022 Dec; 387(23):2126-2137. PubMed ID: 36477032
[TBL] [Abstract][Full Text] [Related]
35. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
36. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
Segal N; Ber Y; Benjaminov O; Tamir S; Yakimov M; Kedar I; Rosenbaum E; Sela S; Ozalvo R; Shavit-Grievink L; Keder D; Baniel J; Margel D
Ann Oncol; 2020 Nov; 31(11):1545-1552. PubMed ID: 32958357
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.
Hao S; Discacciati A; Eklund M; Heintz E; Östensson E; Elfström KM; Clements MS; Nordström T
JAMA Oncol; 2022 Nov; 9(1):88-94. PubMed ID: 36355382
[TBL] [Abstract][Full Text] [Related]
38. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.
Bratt O; Godtman RA; Jiborn T; Wallström J; Akre O; Carlsson S; Nordström T; Thimansson E; Alterbeck M; Zackrisson S; Hugosson J; Bjartell A; Lantz A
Eur Urol; 2024 Mar; 85(3):207-214. PubMed ID: 38042646
[TBL] [Abstract][Full Text] [Related]
39. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]